FGFR3 Antibody (136334) [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # FAB766B
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Western Blot
Label
Biotin
Antibody Source
Recombinant Monoclonal Mouse IgG1 Clone # 136334
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Pool of NS0-derived recombinant human FGF R3 alpha (IIIb) and Sf21-derived FGF R3 alpha (IIIc)
Specificity
Detects
the IIIb and IIIc isoforms of human FGF R3 in direct ELISAs and Western
blots.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for FGFR3 Antibody (136334) [Biotin]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: FGFR3
Long Name
Fibroblast Growth Factor Receptor 3
Alternate Names
CD333, CEK, FGF R3, JTK4
Gene Symbol
FGFR3
Additional FGFR3 Products
Product Documents for FGFR3 Antibody (136334) [Biotin]
Product Specific Notices for FGFR3 Antibody (136334) [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...